Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amisulpride

FDA-approved product (solution, intravenous), marketed as Barhemsys.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Amisulpride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzamides
FDA pharmacologic class
Dopamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Amisulpride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amisulpride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery

    NCT07631910 · start 2026-07-01

    Registered record
    Registry ID
    NCT07631910
    Conditions
    Nausea and Vomiting, Postoperative
    Interventions
    Amisulpride Injection; Dexamethasone (intravenous); Transcutaneous electrical acupoint stimulation (TEAS)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2026-10-31
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Postoperative
    InterventionAmisulpride Injection; Dexamethasone (intravenous); Transcutaneous electrical acupoint stimulation (TEAS)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings

    NCT07348172 · start 2026-03-01

    Registered record
    Registry ID
    NCT07348172
    Conditions
    Drug Liking
    Interventions
    Amisulpride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2028-03-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Liking
    InterventionAmisulpride; Placebo
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

    NCT07494305 · start 2026-01-23

    Registered record
    Registry ID
    NCT07494305
    Conditions
    Bipolar I Disorder
    Interventions
    LB-102; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-23
    Completion
    2028-02
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionLB-102; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery

    NCT06887621 · start 2025-04-10

    Registered record
    Registry ID
    NCT06887621
    Conditions
    Post Operative Nausea and Vomiting (PONV)
    Interventions
    Encapsulated amisulpride 50 mg (matched for color, weight, smell and size); Encapsulated placebo (matched for color, weight, smell and size)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-04-10
    Completion
    2027-03-31
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Operative Nausea and Vomiting (PONV)
    InterventionEncapsulated amisulpride 50 mg (matched for color, weight, smell and size); Encapsulated placebo (matched for color, weight, smell and size)
    PhasePhase 2
    Registry statusActive not recruiting

  • Magnetic Seizure Therapy for Psychotic Disorders

    NCT06581302 · start 2024-09-01

    Registered record
    Registry ID
    NCT06581302
    Conditions
    Psychotic Disorders
    Interventions
    Magnetic seizure therapy by Magnetic stimulator; Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-09-01
    Completion
    2025-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders
    InterventionMagnetic seizure therapy by Magnetic stimulator; Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
    PhaseNot applicable
    Registry statusRecruiting

  • Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

    NCT05546359 · start 2024-01-18

    Registered record
    Registry ID
    NCT05546359
    Conditions
    Nausea and Vomiting, Postoperative
    Interventions
    Amisulpride Injection; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2024-01-18
    Completion
    2025-06-03
    Enrolment
    453

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Postoperative
    InterventionAmisulpride Injection; Dexamethasone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Effects of a Single Dose of Amisulpride on Functional Brain Changes

    NCT05347199 · start 2022-05-17

    Registered record
    Registry ID
    NCT05347199
    Conditions
    Major Depressive Disorder
    Interventions
    Amisulpride Pill; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-05-17
    Completion
    2023-09-25
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAmisulpride Pill; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Psychobiological Mechanisms Underlying Chronic Pain

    NCT04674670 · start 2021-11-01

    Registered record
    Registry ID
    NCT04674670
    Conditions
    Fibromyalgia; Pain, Chronic; Chronic Pain, Widespread
    Interventions
    Bromocriptine Mesylate Capsules; Amisulpride 400 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-11-01
    Completion
    2023-07-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia; Pain, Chronic; Chronic Pain, Widespread
    InterventionBromocriptine Mesylate Capsules; Amisulpride 400 MG; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

    NCT04849650 · start 2021-06-03

    Registered record
    Registry ID
    NCT04849650
    Conditions
    Renal Disease, End Stage
    Interventions
    Amisulpride IV; Amisulpride Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-03
    Completion
    2021-10-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Disease, End Stage
    InterventionAmisulpride IV; Amisulpride Oral Tablet
    PhasePhase 1
    Registry statusCompleted

  • Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

    NCT04446234 · start 2021-05

    Registered record
    Registry ID
    NCT04446234
    Conditions
    Schizophrenia
    Interventions
    Risperidone; Aripiprazole; Ziprasidone; Amisulpride; Quetiapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-05
    Completion
    2022-12-31
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone; Aripiprazole; Ziprasidone; Amisulpride +1 more
    PhasePhase 4
    Registry statusUnknown

  • SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia

    NCT04528095 · start 2020-12

    Registered record
    Registry ID
    NCT04528095
    Conditions
    Treatment-resistant Schizophrenia
    Interventions
    Clozapine; MECT; DBS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-12
    Completion
    2022-12
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment-resistant Schizophrenia
    InterventionClozapine; MECT; DBS
    PhasePhase 3
    Registry statusUnknown

  • Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

    NCT04529226 · start 2020-11-26

    Registered record
    Registry ID
    NCT04529226
    Conditions
    Psychosis; Intellectual Disability
    Interventions
    Clozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-11-26
    Completion
    2025-12-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis; Intellectual Disability
    InterventionClozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    PhasePhase 2
    Registry statusUnknown

  • Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia

    NCT04533724 · start 2020-10-01

    Registered record
    Registry ID
    NCT04533724
    Conditions
    Negative Symptom; Schizophrenia; Amisulpride; Gut Microbiomes
    Interventions
    Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2020-10-01
    Completion
    2022-09-30
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNegative Symptom; Schizophrenia; Amisulpride; Gut Microbiomes
    InterventionAmisulpride
    PhaseEarly phase 1
    Registry statusUnknown

  • Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

    NCT04218981 · start 2020-01-15

    Registered record
    Registry ID
    NCT04218981
    Conditions
    Common Mental Disorder
    Interventions
    Antipsychotic drugs; Mood stabilizer; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-01-15
    Completion
    2023-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommon Mental Disorder
    InterventionAntipsychotic drugs; Mood stabilizer; Paroxetine
    PhaseNot applicable
    Registry statusCompleted

  • Amisulpride Treatment for BPSD in AD Patients

    NCT04341467 · start 2019-12-01

    Registered record
    Registry ID
    NCT04341467
    Conditions
    BPSD; Amisulpride; Olanzapine; Dementia of the Alzheimer Type
    Interventions
    Amisulpride; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-12-01
    Completion
    2024-05
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPSD; Amisulpride; Olanzapine; Dementia of the Alzheimer Type
    InterventionAmisulpride; Olanzapine
    PhaseNot applicable
    Registry statusUnknown